在 5%谷胱甘肽中使用静脉硝酸甘油治疗 COVID-19 合并急性失代偿性心力衰竭。
Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.
机构信息
Augusta Hypertension PC, 108 Tharrington Drive, Chapel Hill, NC, USA.
Institute of Pharmacology and Clinical Pharmacology, University Hospital, Duesseldorf, Germany.
出版信息
Am J Cardiovasc Drugs. 2021 Nov;21(6):589-593. doi: 10.1007/s40256-021-00474-w. Epub 2021 Mar 22.
The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.
本文的目的在于阐述一种治疗 2019 冠状病毒病（COVID-19）患者急性失代偿性心力衰竭（ADHF）的新方法。本文所述方法依赖于将静脉用硝酸甘油用 5%谷胱甘肽重新配方，这本身就是新颖的，并且有望不仅提高 ADHF 缓解率，而且降低 COVID-19 患者心力衰竭并发症的风险。
Zotero 插件